S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: Asian shares meander after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NYSE:HIMS

Hims & Hers Health (HIMS) Stock Price, News & Analysis

$15.74
-0.09 (-0.57%)
(As of 03/27/2024 ET)
Today's Range
$15.67
$16.19
50-Day Range
$8.32
$16.72
52-Week Range
$5.65
$17.16
Volume
3.86 million shs
Average Volume
4.67 million shs
Market Capitalization
$3.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.45

Hims & Hers Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.55 Rating Score
Upside/​Downside
14.5% Downside
$13.45 Price Target
Short Interest
Bearish
9.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of Hims & Hers Health in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$5.56 M Sold Last Quarter
Proj. Earnings Growth
130.00%
From $0.10 to $0.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.67 out of 5 stars

Medical Sector

460th out of 939 stocks

Offices & Clinics Of Medical Doctors Industry

3rd out of 7 stocks

HIMS stock logo

About Hims & Hers Health Stock (NYSE:HIMS)

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.

HIMS Stock Price History

HIMS Stock News Headlines

3 Stocks With Unusual Call Option Activity
When traders stampede into call options, it typically means they expect an event to come, pushing the underlying stock higher soon. Because options expire at a given date, these traders must get their thesis right before expiration or risk losing their entire investment.
3 Stocks With Unusual Call Option Activity (HIMS)
Three stocks reported rising call option buying activity could see even higher prices soon. Analysts see the writing on the wall, and traders stampeded in
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
LifeMD Shares Come Back to Life on GLP-1 Business Growth (HIMS)
LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Can WeightWatchers Regain its Mojo after Oprah Steps Down? (HIMS)
WW International Inc. (NASDAQ: WW) (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD).
Can WeightWatchers Regain Its Mojo after Oprah Steps Down?
WW International Inc. NASDAQ: WW (WeightWatchers) has had a disastrous 2024, with its shares collapsing 66.7% year-to-date (YTD). The company made a praiseworthy strategic pivot in 2023, acquiring Sequence Inc. to enter into the GLP-1 clinical weight loss space, gaining the ability to prescribe medications like Novo Nordisk A/V NYSE: NVO owned Ozempic and Wegovy and Eli Lilly& Co. NYSE: LLY GLP-1 agonists like Mounjaro and Zepbound.
Hims & Hers Stock Rises On Stimulating Earnings Growth
Hims & Hers Inc. NYSE: HIMS is a telehealth platform in the medical sector that has turned the corner into GAAP profitability. The company got its start offering convenient, frictionless and discreet erectile dysfunction (ED) prescription solutions for men but has since expanded its offering into primary care and health and wellness products, including weight loss solutions for men and women.
Hims & Hers Health (NYSE:HIMS) Sets New 1-Year High at $17.15
HIMS Nov 2024 18.000 call
HIMS Jul 2025 25.000 call
Check Out What Whales Are Doing With HIMS
HIMS Apr 2024 20.000 put
HIMS Apr 2024 25.000 call
HIMS Jul 2024 25.000 call
HIMS Apr 2024 12.000 put
See More Headlines
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Offices & clinics of medical doctors
Sub-Industry
N/A
Fax
N/A
Employees
1,046
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.45
High Stock Price Target
$17.00
Low Stock Price Target
$10.00
Potential Upside/Downside
-14.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.55
Research Coverage
11 Analysts

Profitability

Net Income
$-23,550,000.00
Pretax Margin
-2.47%

Debt

Sales & Book Value

Annual Sales
$872 million
Book Value
$1.61 per share

Miscellaneous

Free Float
146,483,000
Market Cap
$3.37 billion
Optionable
Optionable
Beta
0.89
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Andrew DudumMr. Andrew Dudum (Age 35)
    Co-Founder, Chairman & CEO
    Comp: $1.7M
  • Mr. Yemi Okupe (Age 38)
    Chief Financial Officer
    Comp: $804.05k
  • Ms. Melissa BairdMs. Melissa Baird (Age 46)
    Chief Operating Officer
    Comp: $917.67k
  • Ms. Irene A. Becklund (Age 39)
    Senior VP, Controller & Principal Accounting Officer
    Comp: $361.12k
  • Ms. Soleil Teubner Boughton (Age 45)
    Chief Legal Officer & Corporate Secretary
    Comp: $782.66k
  • Mr. Mike Chi (Age 44)
    Chief Marketing Officer
    Comp: $514.77k
  • Dr. Patrick Carroll M.D. (Age 66)
    Chief Medical Officer, Member of Medical Advisory Board & Director
    Comp: $27.03k
  • Ms. Khobi Brooklyn
    Chief Communications Officer
  • Ms. Amee Parekh
    Senior Vice President of Human Resources
  • Dr. Peter Stahl M.D.
    Senior VP & Member of Medical Advisory Board

HIMS Stock Analysis - Frequently Asked Questions

Should I buy or sell Hims & Hers Health stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There are currently 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIMS shares.
View HIMS analyst ratings
or view top-rated stocks.

What is Hims & Hers Health's stock price target for 2024?

11 Wall Street analysts have issued 1 year price objectives for Hims & Hers Health's stock. Their HIMS share price targets range from $10.00 to $17.00. On average, they predict the company's share price to reach $13.45 in the next twelve months. This suggests that the stock has a possible downside of 14.5%.
View analysts price targets for HIMS
or view top-rated stocks among Wall Street analysts.

How have HIMS shares performed in 2024?

Hims & Hers Health's stock was trading at $8.90 at the beginning of the year. Since then, HIMS stock has increased by 76.8% and is now trading at $15.7350.
View the best growth stocks for 2024 here
.

Are investors shorting Hims & Hers Health?

Hims & Hers Health saw a decrease in short interest in the month of February. As of February 29th, there was short interest totaling 12,650,000 shares, a decrease of 6.1% from the February 14th total of 13,470,000 shares. Based on an average trading volume of 4,040,000 shares, the short-interest ratio is presently 3.1 days. Approximately 9.1% of the company's stock are short sold.
View Hims & Hers Health's Short Interest
.

When is Hims & Hers Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our HIMS earnings forecast
.

How were Hims & Hers Health's earnings last quarter?

Hims & Hers Health, Inc. (NYSE:HIMS) announced its earnings results on Monday, February, 26th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.03. The business earned $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative trailing twelve-month return on equity of 7.21% and a negative net margin of 2.70%. Hims & Hers Health's quarterly revenue was up 47.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.05) EPS.

What guidance has Hims & Hers Health issued on next quarter's earnings?

Hims & Hers Health issued an update on its first quarter 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $267.0 million-$272.0 million, compared to the consensus revenue estimate of $251.3 million.

Who are Hims & Hers Health's major shareholders?

Hims & Hers Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.69%), Vanguard Group Inc. (6.62%), Forerunner Ventures Management LLC (4.60%), Nuveen Asset Management LLC (1.67%), Dimensional Fund Advisors LP (1.01%) and Franklin Resources Inc. (0.85%). Insiders that own company stock include Alex Bard, Andrew Dudum, David B Wells, David B Wells, Irene Becklund, Jack Abraham, Jules A Maltz, Lynne Chou O'keefe, Melissa Baird, Oluyemi Okupe, Patrick Harrison Carroll, Soleil Boughton and Spencer Lee.
View institutional ownership trends
.

How do I buy shares of Hims & Hers Health?

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:HIMS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners